A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...

C3Spectra is pleased to officially announce its approval by the Federal Communications Commission (FCC) as an Automated Frequency Coordination (AFC) operator. This milestone positions the company to ...

Utilizing new data from the Yardi® Matrix affordable housing database, the latest Yardi Matrix report on affordable housing explores the sector's current state of deliveries and ...

MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

Chapman was also named “BioTechnology Innovator of the Year” in 2024, in the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough. These recognitions highlight ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its price objective raised by Leerink Partners from $18.00 to $20.00 in a research report issued to clients and investors on Monday ...